1439 related articles for article (PubMed ID: 11095440)
1. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
2. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
[TBL] [Abstract][Full Text] [Related]
3. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.
Franco C; Johannsson G; Bengtsson BA; Svensson J
J Clin Endocrinol Metab; 2006 Nov; 91(11):4408-14. PubMed ID: 16940452
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
Toogood AA; Shalet SM
J Clin Endocrinol Metab; 1999 Jan; 84(1):131-6. PubMed ID: 9920073
[TBL] [Abstract][Full Text] [Related]
7. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
Amin S; Riggs BL; Melton LJ; Achenbach SJ; Atkinson EJ; Khosla S
J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
[TBL] [Abstract][Full Text] [Related]
8. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
[TBL] [Abstract][Full Text] [Related]
9. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
Burman P; Johansson AG; Siegbahn A; Vessby B; Karlsson FA
J Clin Endocrinol Metab; 1997 Feb; 82(2):550-5. PubMed ID: 9024252
[TBL] [Abstract][Full Text] [Related]
13. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
14. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
Rosenfalck AM; Fisker S; Hilsted J; Dinesen B; Vølund A; Jørgensen JO; Christiansen JS; Madsbad S
Growth Horm IGF Res; 1999 Apr; 9(2):96-105. PubMed ID: 10373342
[TBL] [Abstract][Full Text] [Related]
15. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
Elgzyri T; Castenfors J; Hägg E; Backman C; Thorén M; Bramnert M
Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
[TBL] [Abstract][Full Text] [Related]
18. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
[TBL] [Abstract][Full Text] [Related]
19. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
20. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender.
Johannsson G; Bjarnason R; Bramnert M; Carlsson LM; Degerblad M; Manhem P; Rośen T; Thorén M; Bengtsson BA
J Clin Endocrinol Metab; 1996 Apr; 81(4):1575-81. PubMed ID: 8636370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
